Why Roche’s Phase III bet on prasinezumab is bigger than its Phase IIb result suggests
Roche and BMS present updated prasinezumab and BMS-986446 data at AD/PD 2026. What it means for Phase III plans and tau targeting. Read the analysis.
Scynexis expands SCY-247 program with IV SAD and MAD trial launch
SCYNEXIS advances IV SCY-247 into Phase 1 for invasive candidiasis. Explore what this means for resistance and regulation.
INTENT Biologics secures FDA pediatric waiver, clears path to late-stage DFU trial for PEP Biologic
The U.S. Food and Drug Administration (FDA) has granted INTENT Biologics a full pediatric study waiver for its lead candidate, PEP Biologic, under IND 019567. The waiver, part of an agreed Initial Pediatric Study Plan (iPSP), applies to the product’s adult-focused development for diabetic foot ulcers (DFUs), a serious chronic wound indication preparing for pivotal […]
Can Alessa’s Enolen implant change how early-stage prostate cancer is treated?
Alessa’s Enolen earns FDA fast track for localized prostate cancer. Find out how this implant could redefine early-stage treatment and challenge current norms.